Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Total Current Liabilities (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Total Current Liabilities for 3 consecutive years, with $5.3 million as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Total Current Liabilities fell 93.25% year-over-year to $5.3 million, compared with a TTM value of $5.3 million through Sep 2024, down 93.25%, and an annual FY2023 reading of $53.2 million, up 826.11% over the prior year.
  • Total Current Liabilities was $5.3 million for Q3 2024 at Oramed Pharmaceuticals, up from $3.7 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $78.2 million in Q3 2023 and bottomed at $1.1 million in Q2 2023.
  • Average Total Current Liabilities over 3 years is $18.6 million, with a median of $6.3 million recorded in 2022.
  • The sharpest move saw Total Current Liabilities soared 1098.08% in 2023, then tumbled 93.25% in 2024.
  • Year by year, Total Current Liabilities stood at $5.7 million in 2022, then soared by 826.11% to $53.2 million in 2023, then tumbled by 90.09% to $5.3 million in 2024.
  • Business Quant data shows Total Current Liabilities for ORMP at $5.3 million in Q3 2024, $3.7 million in Q2 2024, and $33.6 million in Q1 2024.